Summary
Amends the National Health (Pharmaceutical Benefits) Regulations 1960, which administer Australia's Pharmaceutical Benefits Scheme (PBS). The PBS provides subsidized prescription medicines to eligible Australians through government-controlled pricing, drug listing approvals, and supply chain regulations. The amendment modifies aspects of this regulatory framework.
Reason
The Pharmaceutical Benefits Scheme represents a massive intervention in the healthcare market that distorts price signals, reduces competition, and creates moral hazard. Government price controls on pharmaceuticals discourage innovation and R&D investment, while bureaucratic approval processes delay access to new, potentially life-saving treatments. The scheme's administrative costs are astronomical and ultimately borne by taxpayers. By removing price as a rationing mechanism, the PBS creates shortages and misallocates resources. The unintended consequences - reduced drug variety, supply constraints, increased waiting times, and stifled medical innovation - far outweigh any benefits of subsidized access, which could be better achieved through private insurance or targeted assistance programs without crippling the entire pharmaceutical market.